|
|
|
|
|
Bladder Cancer Advocacy Network (BCAN) Think Tank Conference Highlights
|
|
|
|
|
|
BCAN 2023 Patient-Centered Clinical Young Investigator Awardee
|
|
| Identifying Individual and Community-Level Drivers of Disparities in Bladder Cancer Clinical Trials Participation
|
| Rishi Sekar, MD
|
| Rishi Sekar highlighted the significant disparities in bladder cancer clinical trial participation, particularly among socially vulnerable communities. His research revealed that patients in these communities are less likely to be aware of, discuss, or participate in clinical trials, despite having higher bladder cancer mortality rates. The findings underscore the need to expand clinical trial infrastructure in disadvantaged areas to promote equitable cancer care. |
|
|
|
|
|
| Exploring FGFR3 Inhibition as a Sensitizing Agent to Nectin-4 ADC Therapy in Urothelial Carcinoma
|
| Sean Clark-Garvey, MD, MPH
|
| Sean Clark-Garvey presents his group’s work exploring Fibroblast Growth Factor 3 inhibition as a sensitizing agent to Nectin-4 antibody-drug conjugate therapy in urothelial carcinoma. FGFR3 activating alterations and Nectin-4 expression is enriched in luminal subtypes of muscle-invasive and metastatic urothelial carcinoma and mUC, with expression positively correlated. Membranous Nectin-4 expression is upregulated in cell lines harboring activating FGFR3 alterations following treatment with erdafitinib, and the effect is specific to FGFR3 inhibition.
|
|
|
|
|
|
|
|
|
|
|
|
Bridging Evidence Generation to Practice in Bladder Cancer Care with Implementation Science
|
|
| Bladder Cancer Care Implementation: NCCN Bladder Cancer Guidelines
|
| Thomas Flaig, MD
|
| Thomas Flaig discusses the role of the National Comprehensive Cancer Network (NCCN) in bladder cancer care, highlighting the importance of the NCCN Guidelines, which are continuously updated to reflect new data. He emphasizes the global impact of these guidelines, including their adaptation to resource-constrained settings through NCCN Harmonized Guidelines.
|
|
|
|
|
|
| Implementation of Smoking Cessation for Patients with Bladder Cancer |
| Marc Bjurlin, DO, MSc |
| Marc Bjurlin discusses the critical role of smoking cessation in improving outcomes for bladder cancer patients. Smoking is a significant risk factor, responsible for nearly 50% of bladder cancer cases, and continued smoking exacerbates recurrence rates, disease progression, surgical complications, and mortality. Dr. Bjurlin highlighted gaps in practice, including the lack of counseling and prescription of cessation aids, and the importance of patient education on the link between smoking and bladder cancer. |
|
|
|
|
|
| A Rapid Intro to Implementation Science
|
| Kristian Stensland, MD, MPH, MS
|
| Kristian Stensland provided an overview of implementation science, emphasizing its role in bridging the gap between clinical trial efficacy and real-world effectiveness. He highlighted the importance of context assessment and the use of determinant and outcome frameworks to design targeted interventions that improve the delivery of evidence-based care, such as increasing the use of post-TURBT gemcitabine to reduce bladder cancer recurrence rates.
|
|
|
|
|
|
| Disrupting the Paradigm of First-line Therapy In Metastatic Urothelial Cancer
|
| Andrea B. Apolo, MD
|
| Andrea Apolo discussed major advances in first-line therapy for metastatic urothelial carcinoma, highlighting two pivotal phase III trials: EV-302 and CheckMate 901. EV-302 demonstrated that the combination of enfortumab vedotin and pembrolizumab nearly doubled overall survival compared to chemotherapy, establishing it as the new standard of care.
|
|
|
|
|
|
| Using Implementation Science to Improve Surveillance for Early-Stage Bladder Cancer |
| Florian Schroeck, MD, MS |
| Florian Schroeck highlights the need to improve risk-adapted surveillance for non-muscle invasive bladder cancer. A study within the VA system revealed poor adoption of risk-aligned surveillance, leading to unnecessary procedures for low-risk patients. Using implementation science frameworks, Schroeck's team identified barriers, selected targeted strategies, and improved surveillance accuracy and documentation, particularly for low-risk patients.
|
|
|
|
|
|
|
|
|
|
|
Advancing Bladder Cancer Care: Innovative Research and New Treatment Strategies |
|
|
|
|
|
|
Novel Bladder Cancer Treatment: Mechanisms, Clinical Findings, and Implications
|
Patrick Soon-Shiong, MD
Ashish Kamat and Patrick Soon-Shiong explore the clinical development and FDA approval of Anktiva for bladder cancer. Dr. Soon-Shiong outlines the journey from initial studies in BCG-naive and BCG-unresponsive patients to approval.
|
|
|
|
|
|
|
|
|
|
|
|
BOND-003 Trial: Cretostimogene Grenadenorepvec Shows Promise in BCG-Unresponsive NMIBC
|
Mark Tyson II, MD, MPH
Sam Chang speaks with Mark Tyson about the BOND-003 trial's findings on cretostimogene grenadenorepvec for treating BCG-unresponsive carcinoma in situ of the bladder. Dr. Tyson explains the dual-action mechanism of the drug, combining direct tumor cell destruction with enhanced immune response activation.
|
|
|
|
|
|
|
|
|
|
|
| SunRISe-5 Trial: Evaluating TAR-200 for Recurrent High-Risk Non-Muscle Invasive Bladder Cancer |
| Sima Porten, MD, MPH |
| Sima Porten provides an overview of the SunRISe-5 trial, a Phase III study evaluating TAR-200, a novel drug delivery system for patients with recurrent high-risk non-muscle invasive bladder cancer who have not responded to BCG treatment. |
|
|
|
|
|
|
|
|
|
